CATEGORY
Antibody Vaccines
Beroe LiVE.Ai™
AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Antibody Vaccines.
Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.
Category Alerts
Brii Biosciences Exercises Option in Greater China for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B.
July 12, 2022Brii Biosciences Announces the Commercialization of Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China.
July 14, 2022Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Antibody Vaccines
Antibody Vaccines Industry Benchmarks
Savings Achieved
(in %)
The average annual savings achieved in Antibody Vaccines category is 5.40%
Payment Terms
(in days)
The industry average payment terms in Antibody Vaccines category for the current quarter is 73.4 days
Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™
Category Strategy and Flexibility
Engagement Model
Supply Assurance
Sourcing Process
Supplier Type
Pricing Model
Contract Length
SLAs/KPIs
Lead Time
Supplier Diversity
Targeted Savings
Risk Mitigation
Financial Risk
Sanctions
AMEs
Geopolitical Risk
Cost Optimization
Price per Unit Competitiveness
Specification Leanness
Minimum Order Quality
Payment Terms
Inventory Control
The World’s first Digital Market Analyst
Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions
Antibody Vaccines Suppliers

Find the right-fit antibody vaccines supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.



Use the Antibody Vaccines market, supplier and price information for category strategy creation and Quaterly Business Reviews (QRBs)
Antibody Vaccines market report transcript
Antibody Vaccines Global Market Outlook:
Market Growth: CAGR growth rate: $3.28 Billion in 2018 and expected to reach $4.19 Billion by 2022, growing at a CARG of 6.2 percent
Reduction in availability of targeted researchers and physician is expected, due to outbreak of COVID, which is impacting the antibody vaccine
development and analytical testing services
Due to the COVID breakdown, demand for developing antibody vaccine for novel coronavirus is increasing and hence, pharmaceutical
companies are collaborating with research institutions to enhance the speed of antibody vaccine development
Porter's Analysis on Antibody Vaccines
Supplier Power
- Supplier power is medium as most of the buyers enter into strategic relationships with the preferred suppliers
- Most of the buyers have particular set of suppliers to be considered for the development process. This is based upon the various technologies and
processes available.
Barriers to New Entrants
- Set up and scale up of mammalian cell cultures require time.
- Buyers prefer to go for strategic relationships in this category. Suppliers currently existing in the market have working relationships with various buyers and the entry of a new entrant would be difficult.
Intensity of Rivalry
- The rivalry faced by the CMOs is not from the direct competitors, but rather an influx of capacity from the players who were product manufacturers earlier.
- The differences in the established volume, processes, technologies differentiates the various suppliers in the supply space.
- The CMO space is growing at a rate greater than the increase in demand.
Threat of Substitutes
- Monoclonal antibodies operate by mimicking the natural defense mechanism of the human body, and is really effective the areas of Cancer and auto immune diseases.
- Unless a new technology/process can find an alternative for the treatment, the threat of substitute is really low.
Buyer Power
-
The utilization rates of the supplier facilities are expected to drop going foreword as the suppliers and buyers are expanding at a rate higher than the
increase in supply. -
Most of the buyers outsource high volumes to a supplier often leading to the allotment of a dedicated space.